The physiologic actions of retinoic acids (RAs) are mediated through RA receptors (RARs) and retinoid X receptors (RXRs). The RAR␣ gene has drawn particular attention because it is the common target in all chromosomal translocations in acute promyelocytic leukemia (APL), a unique model in cancer research that responds to the effect of RA. In the great majority of patients with APL, RAR␣ is fused to the PML gene as a result of the t(15;17) translocation. Three distinct types of PML-RAR␣ transcripts, long (L), short (S), and variant (V), were identified. The V-type is characterized by truncation of exon 6 of PML and in some cases by the insertion of a variable ''spacer'' sequence between the truncated PML and RAR␣ mRNA fusion partners, although the precise mechanisms underlying formation of the V-type transcript remain unclear. To get further insights into the molecular basis of the t(15;17), we sequenced the entire genomic DNA region of RAR␣. Of note, all previously reported ''spacer'' sequences in V-type transcripts were found in intron 2 of the RAR␣ gene and most of these sequences were flanked by gt splice donor sites. In most cases, these ''cryptic'' coding sequences maintained the ORF of the chimeric transcript. Interestingly, two cases with a relatively long spacer sequence showed APL cellular and clinical resistance to RA treatment. In these cases, the aberrant V-type PML-RAR␣ protein displayed increased affinity to the nuclear corepressor protein SMRT, providing further evidence that RA exerts the therapeutic effect on APL through modulation of the RAR-corepressor interaction. Finally, among patients with the L-or S-type PML-RAR␣ fusion transcript, some consensus motifs were identified at the hotspots of the chromosome 17q breakpoints within intron 2 of RAR␣, strengthening the importance of this intron in the molecular pathogenesis of APL. R etinoic acids (RAs) play a wide variety of physiological roles during embryogenesis and adult life. The effects of RAs are mediated through two families of nuclear receptors, RA receptors (RARs) and retinoid X receptors (RXRs), each including three members, ␣, ␤, and ␥. Whereas RXRs can form homodimers, RARs need to heterodimerize with RXRs to constitute a functional receptor. These receptors bind to DNA motifs known as RAREs (RA response elements), located in the regulatory sequences of RA target genes (1). The transregulatory properties of RAR͞RXR are determined, in a ligand-dependent manner, by their interaction with two protein complexes, nuclear receptor corepressor (CoR) and coactivator (2). Each member of the RAR and RXR families is encoded by a unique gene, which may generate a number of isoforms with distinct N-terminal sequences through alternative use of 5Ј exons (3). The combinatorial expression of both gene families, as well as their isoforms, varies across different tissue͞cell types at distinct stages of development, contributing to the biological complexity of RA signaling (1-4).
R
etinoic acids (RAs) play a wide variety of physiological roles during embryogenesis and adult life. The effects of RAs are mediated through two families of nuclear receptors, RA receptors (RARs) and retinoid X receptors (RXRs), each including three members, ␣, ␤, and ␥. Whereas RXRs can form homodimers, RARs need to heterodimerize with RXRs to constitute a functional receptor. These receptors bind to DNA motifs known as RAREs (RA response elements), located in the regulatory sequences of RA target genes (1) . The transregulatory properties of RAR͞RXR are determined, in a ligand-dependent manner, by their interaction with two protein complexes, nuclear receptor corepressor (CoR) and coactivator (2) . Each member of the RAR and RXR families is encoded by a unique gene, which may generate a number of isoforms with distinct N-terminal sequences through alternative use of 5Ј exons (3) . The combinatorial expression of both gene families, as well as their isoforms, varies across different tissue͞cell types at distinct stages of development, contributing to the biological complexity of RA signaling (1) (2) (3) (4) .
Over the last decade, the biomedical importance of RAR␣ has been highlighted by its involvement in the pathogenesis of acute promyelocytic leukemia (APL) (2, (5) (6) (7) (8) . The chromosome translocation t(15;17), a hallmark for APL (9) , disrupts the PML gene on chromosome 15 and the RAR␣ gene on chromosome 17 (10) (11) (12) , resulting in chimeric PML-RAR␣ and RAR␣-PML fusion genes. On the other hand, the ability of all-trans RA (ATRA) to induce neutrophilic differentiation of APL cells is often cited as a triumph of molecular understanding of leukemia (6) . Extensive studies have shown that the breakpoints on chromosome 17 are consistently located in the second intron of the RAR␣ gene, but on chromosome 15, there are different breakpoint cluster regions, namely bcr1, bcr2, and bcr3 located in intron 6, exon 6, and intron 3, respectively (13) (14) (15) (16) (17) (18) (19) (20) (21) . As a result, three distinct types of PML-RAR␣ transcripts can be generated in different patients. About 70% of patients with APL have bcr-1 or long (L)-type isoform, resulting from the fusion between PML exon 6 (P6) and RAR␣ exon 3 (R3), and 20% of patients with APL have bcr-3 or short (S)-type isoform, resulting from fusion between PML exon 3 (P3) and R3. The third type, bcr-2 or variant (V)-type isoform, accounting for about 10% in APL, is formed through a fusion between the truncated P6(⌬P6) and the R3, frequently with insertion of a sequence into the ⌬P6-R3 joining (spacer) (2) . Formation of L-and S-type isoforms of fusion transcripts is easily understood, whereas the molecular mechanisms responsible for the V-type isoform remain obscure. Some groups have observed clinical and biological features related to these three PML-RAR␣ isoforms. For example, cells harboring V-type transcripts were found to display decreased sensitivity to ATRA (21) and the incidence of V-type isoform is higher in the pediatric population than in adults (22) (23) (24) . In addition, in a small subset of patients with APL with variant chromosomal translocations, t(11, 17)(q23;q21), t(5;17)(q35;q21), t(11;17)(q13;q21), and dup17q21-23, the RAR␣ gene is the common target and is fused to corresponding partner genes PLZF, NPM, NuMA, and STAT5b. All these data emphasize the importance of the RAR␣ gene in the pathogenesis of APL (2) .
To get a better understanding of the structural organization of the RAR␣ gene and to study the molecular mechanism of the genomic breakpoints and mRNA splicing of the PML-RAR␣ gene, particularly the V-type isoform, we sequenced the full genomic RAR␣ gene. We show that the use of cryptic coding sequences in RAR␣ intron 2 is critical for maintaining the ORF of the fusion gene and that a subset of V-type isoforms mediates RA resistance because of its aberrant binding affinity to the CoR protein complex.
Materials and Methods

Shotgun Sequencing Strategy and Computer Analysis of Sequence
Data. BAC clone RP11-205M17 was kindly provided by J. Murray (University of Iowa). This BAC clone contains the full-length RAR␣ gene (25) . BAC DNA was sonicated and size-fractionated for shotgun sequencing as described (26) . With sufficient coverage, sequences were assembled and finished with the help of the PHRED/PHRAP/CONSED package (http:͞͞www.phrap.org). Several algorithms and databases were used to analyze the genomic sequence of RAR␣. (i) Repetitive sequences were determined with the software REPEATMASKER (http:͞͞repeatmasker.genome. washington.edu͞cgi-bin͞RepeatMasker). (ii) GC content was sought with GRAIL 1.3, which was also used to identify the exons with GENESCAN, GENIE, GENID, FGENES (these five programs are from http:͞͞rgd.mcw.edu͞METAGENE). (iii) cDNA was aligned with genomic sequence of RAR␣ with SIM4 and BLAST to give a view of the actual splicing sites. (iv) For the analysis of regulatory sequences in the putative promoter region, NNPP (Promoter Prediction by Neural Network), PROMOTER SCAN, SPLICE-VIEW(WEBGENE), TESS, and TRANSFAC were applied together to make a comprehensive prediction. (v) Sequences flanking breakpoints in intron 2 were analyzed with the online software MEME.
Patient Data. V-type isoform PML-RAR␣. Published data from 18 patients with APL with V-type isoforms were collected (16, 24) . In this work, reverse transcription (RT)-PCR and sequence analysis were carried out on three patients. Briefly, total RNA was extracted from the APL samples by the acid-guanidinium-phenol-chloroform method (27) , whereas reverse transcription and subsequent PCR were carried out by using reported conditions (28) . RT-PCR products were purified with the QIAquick Gel Extraction kit (Qiagen, Hilden, Germany), subcloned into pGEM-T-Easy vector (Promega), and then sequenced.
Protein Interaction Assay. Plasmids. The RAR␣ and L-type PML-RAR␣ (in pSG5 vector) expression vectors were as described (29) . The V-type PML-RAR␣ (cases F1 and G-S448) expression vectors were constructed by replacing the fusion region of L-type PML-RAR␣ with the fusion region by using appropriate restriction endonucleases or fusion-PCR technology. A glutathione Stransferase (GST)-SMRT peptide (residues 983-1172) containing the receptor interaction domain was kindly provided by R. Evans (The Salk Institute). The protein secondary structure prediction of the spacer sequence of F1 case was analyzed with the online software PHDsec (http:͞͞cubic.bioc.columbia.edu͞predictprotein). F1-⌬1 and F1-⌬2 PML-RAR␣ expression vectors were constructed, respectively, by deleting a short motif of 5 amino acids, or the total sequence, of the spacer of the F1 case (Fig. 2C) .
In vitro protein-binding assay. The GST pull-down assay for interaction between different RARs and SMRT protein was performed as described (29) .
Gel-shift DNA-binding assay. The RARE probe DR5G was used in this experiment (29) . The in vitro-translated proteins were preincubated for 15 min at room temperature in the following buffer: 20 mM Hepes, pH 7.4͞50 mM KCl͞1 mM 2-mercaptoethanol͞10% glycerol͞1 g poly(dI-dC) (Amersham Pharmacia Biotech, Piscataway, NJ)͞100 g BSA. The 32 P-labeled DR5G probe was then added, and the samples were incubated further at room temperature for 30 min and at 4°C for 30 min. Protein-DNA complexes were resolved on 6% polyacrylamide gels equilibrated in 0.5% TBE buffer (90 mM Tris͞64.6 mM boric acid͞2.5 mM EDTA, pH 8.3). Gels were dried, exposed, and analyzed by a Molecular Imager FX system (Bio-Rad).
Sequences Encompassing the Joining Between RAR␣ and PML Genes in bcr-1 and bcr-2 Patients with APL. Genomic sequences flanking the PML and RAR␣ gene-joining sites were obtained from 16 described patients, 15 with bcr1 rearrangement and 1 with bcr3 rearrangement (16, (30) (31) (32) (33) . In this work, sequences from one patient presenting bcr-2 were also obtained by PCR of genomic DNA with appropriate primers.
Results
Features of the RAR␣ Gene. With the shotgun strategy, we obtained a high-quality complete genomic DNA sequence of the RAR␣ gene in the BAC RP11-205M17 with a length of 138,142 bp. By REPEAT-MASKER analysis, several repeated elements in human DNA were detected. In total, there are 27 short interspersed elements (SINEs) (16 Alu, 3 MIR, 8 simple repeats) and 3 long interspersed elements (LINEs) over this region ( Fig. 1 ). Considering the determined transcription start site (TSS) as the 5Јend (34) and the AATAAA listed in the 3Ј untranslated region (UTR) of several described RAR␣ cDNA sequences as the 3Ј end, the complete genomic DNA sequence of the RAR␣ gene was 39,398 bp (GenBank accession no. AC090426). This sequence of RAR␣ was subjected to comparison with published cDNA and expressed sequence tags (ESTs) available from dbEST, which confirmed the described exon-intron boundaries (25) and established the exact lengths of each exon and intron. Intron 2, which separates the ''classical'' exon 2 and exon 3, is 16,919 bp long, occupying about 43% of the RAR␣ gene. Within this large intron, there is a stretch of sequence corresponding to the 5Ј end (UTR and coding sequence) of the ␣2 isoform. Although this alternatively used exon was named as ''exon 3'' in an early report (3), recent literature prefers not to number this exon (25) . To avoid confusion in nomenclature, we designated this exon as ␣2Ex1 in the present work (Fig. 1) . Hence, the RAR␣ gene should have two alternatively used promoters for the classical exon 1 and the ␣2Ex1, respectively. Examination of a 10-kb region upstream of the classical exon 1 revealed two CpG islands (nucleotides Ϫ463 to Ϫ1 and nucleotides Ϫ1600 to Ϫ1104), but no CCAAT or TATA boxes were observed. This region showed no typical RARE, although some other transcription factor binding sites have been found, such as PEBP2, a homolog of AML-1, known to play a role in granulocytic differentiation (35) (36) (37) and ELP, a transcriptional repressor (38, 39) . The presence of a typical DR5 RARE motif at Ϫ49 bp with regard to the TSS of ␣2Ex1 is in agreement with the observation that the ␣2 isoform is induced by RAs and that there is a dramatic up-regulation of the ␣2 isoform during granulocytic differentiation. ‡ ‡ In addition, as a ''by product'' of this work, we obtained the entire genomic region of the topoisomerase IIA (Topo IIA) gene (accession no. AF071738), which is situated 32,533 bp downstream of the 3Ј end of the RAR␣ gene and composed of 35 exons and 34 introns (Fig. 1) . These results thus extended the partial sequence data of Lang et al. (40) .
Mechanism Involved in V-Type PML-RAR␣ Isoform Formation. It was speculated that the sequence recognized as a spacer between PML and RAR␣ in V-type fusion transcripts may have originated from intron 2 of the RAR␣ gene (16, 17, 24) . To address this issue, we ‡ ‡ Zelent, A., Zhu, J., Lanotte, M., Gallagher, R., Waxman, S., Heyworth, C. M. & Enver, T.
(1997) Blood 90, Suppl., 44a-45a (abstr.).
analyzed all 18 cases with V-type transcripts in the literature (16, 17, 24 ) and 3 cases recently studied in our lab. Fourteen cases were selected for further study with spacer sequences at least 8 bp in length, because shorter spacer sequences could be found at more than one site in the large intron 2, making the analysis difficult. Some reported spacer sequences were different from our genomic RAR␣ gene sequence by 1 or 2 bp, probably because of an error in published sequences or of the existence of single nucleotide polymorphisms (SNPs). Indeed, we found that all 14 spacer sequences of V-type PML-RAR␣ transcripts were located in the second intron of the RAR␣ gene ( Fig. 2A) . Of note, three of the intronic spacer sequences were used twice in distinct patient cells, suggesting a selective effect. As a result, in 13 of 14 patients, the ORFs were maintained although the 3Ј moiety of P6 was lost at the mRNA level. Moreover, at the genomic sequence level, immediately downstream of the spacer, there were splice donor signals observing the ''gt'' rule in 13 of 14 cases (Fig. 2 A) . To confirm the use of these mechanisms in generating the fusion between the ⌬P6 and the intact R3, we analyzed the genomic joining site in two cases, patients F1 and G-E076. As shown in Fig. 2B for the F1 case, in line with a previous report (16) , the genomic sequence alternations were exactly the same as deduced from the spacer sequence at the mRNA level. The breakpoint in PML was located between nucleotides 248-249 of P6 and the breakpoint of RAR␣ was situated between nucleotides 12581-12582 of intron 2, just upstream of a spacer sequence. The sequence of the reciprocal chromosome breakpoint in case G-E076 also perfectly matched the use of spacer sequence in ⌬P6-R3 fusion in mRNA (data not shown). Interestingly, in case G-C205, the spacer sequence was a stretch of 19 bp immediately upstream of R3 (Fig. 2 A) . The most probable explanation for this situation is that RAR␣ gene could be disrupted in a position upstream of this 19-bp sequence and then fused to a ⌬P6.
The distance between the ⌬P6-derived sequence and the 5Ј end of R3 was too close for a functional splicesome to be formed. Of note, the insertion of these 19 bp allowed a ''read-through'' of the ORF. Although the ORF in most V-type PML-RAR␣ transcripts was maintained, in one case (F2), the spacer sequence was not ''inframe,'' which could result in expression of a 3Ј truncated PML protein but not a functional PML-RAR␣ protein. However, in this case, another fusion gene transcript, an S-type isoform, was detected by appropriate reverse transcription (RT)-PCR conditions. Sequence analysis of this RT-PCR product confirmed its origin as a P3-R3 fusion.
A Subset of V-Type PML-RAR␣ with Aberrant Binding to SMRT Protein
Correlates with APL Cellular and Clinical Resistance to ATRA. To investigate possible differences between the L-and V-types of PML-RAR␣ in terms of RA sensitivity, we examined the stability of the binding of in vitro-translated L-and V-type PML-RAR␣ proteins to GST-SMRT in a GST pull-down assay and gel-shift assay under different concentrations of ATRA (Fig. 3A) . In the GST pull-down experiment, wild-type RAR␣ and L-type PML-RAR␣ began to dissociate from GST-SMRT at 10 Ϫ7 to 10 Ϫ6 M ATRA. However, the V-type fusion receptors from two patients showed distinct binding properties to SMRT. Whereas the V-type protein from case G-S448 showed ATRA sensitivity similar to that of the L-type one, the PML-RAR␣ from the F1 case did not dissociate from GST-SMRT even at 10 Ϫ5 M ATRA. Sequencing of the full-length cDNA ruled out a point mutation in the major functional domains of the protein in F1 (data not shown). That the aberrant binding to SMRT was mediated by the ''spacer'' from RAR␣ intron 2 and not by the truncated PML exon 6 was confirmed by the fact that F1 protein with deletion of the spacer (F1-⌬2) restored the sensitivity to the effect of ATRA (Fig. 3A  Upper) . Moreover, when a 5-aa stretch of the spacer, predicted to be a protein-protein interaction motif, was deleted from F1 V-type protein (F1-⌬1; Fig. 2C ), the SMRT binding ability of the fusion receptor was significantly reduced at 10 Ϫ5 M ATRA (Fig. 3A  Upper) . The gel-shift assay, however, may be more sensitive to detect the dissociation of SMRT from PML-RAR␣ and generated concordant data. The dissociation of SMRT from both L-type PML-RAR␣ and G-S448 V-type fusion receptor homodimers could be observed at 10 Ϫ7 M ATRA, whereas all F1-type PML-RAR␣ remained in the complex with SMRT at the same concentration of ATRA, and a smear of bands suggestive of reduced SMRT binding was seen only at 10 Ϫ6 M ATRA. However, the F1-⌬1 and F1-⌬2 (Fig. 3A Lower) PML-RAR␣ proteins could dissociate from SMRT at 10 Ϫ7 M ATRA.
Of note, the clinical data from patient F1 suggested resistance to the therapeutic effect of ATRA. As shown on Fig. 3C , the bone marrow promyelocytes remained at 20% after 72 days of standarddose ATRA therapy. A remission was then achieved when chemotherapy was implemented, but the patient relapsed shortly there- after. Importantly, the previously described G-E076 case had a very similar ''spacer'' sequence to the F1 case (Fig. 2 A) and this patient also showed APL cellular and clinical resistance to ATRA (24) . On the other hand, a number of cases with insertion of a short ''spacer'' responded well to ATRA (24) . Hence, V-type PML-RAR␣ patients seem to be a heterogeneous group with regard to the response to differentiation therapy, a small subset of which have a distinct phenotype compared with classical PML-RAR␣ patients.
Analysis of the Breakpoints Clusters in the RAR␣ Gene. Previous studies showed that the chromosomal breakpoints of RAR␣ were always located in intron 2. Now that the genomic sequence of this intron is available, we tried to address the mechanisms facilitating the translocation through analysis of breakpoint regions in 15 cases with bcr1 rearrangement and in 1 case with bcr3 rearrangement. Although the identification of the breakpoint region was limited because of probe selection, we still found two chromosomal breakage hot spots located near the 3Ј end of intron 2 spanning a 258-bp sequence interval. The first hotspot included 2 breaks within 4 bp, whereas the second one contained 6 breaks within 58 bp. At the sequence level, precise reciprocal fusion without the deletion or insertion of nucleotides was found in all patients. To analyze the possible recognition mechanism of the breakpoints further, MEME software was used to discover candidate consensus patterns. Three patterns were found and named rarabpm1, rarabpm2, and rarabpm3 (Table 1) . Rarabpm2 seems to be a pyrimidine-rich region, rarabpm3 is a ''GC''-rich region, whereas rarabpm1 seems to consist of a pyrimidine-and a ''GC''-rich region (Table 1) . However, these consensus patterns do not correspond to any known specific protein binding sites.
Discussion
One of the characteristics of the PML-RAR␣ fusion gene is the presence of distinct types of PML-RAR␣ transcripts. In most patients with the V-type isoform, the ORFs are still maintained because of an inserted spacer sequence between the ⌬P6 and R3. To explain the formation of the V-type isoform, we initially proposed the following hypothesis. The chromosomal breakpoints in the PML gene should be located within the P6. As a result, not only is the coding region in this exon disrupted, but also the splicing donor signal downstream of P6 is eliminated, which might cause a problem for the protein-coding ability of the PML-RAR␣ fusion gene. However, as suggested by previous data in a few cases (16, 17, 24) , if the ⌬P6 sequence is fused to a region of the RAR␣ intron 2 where short coding sequences with ''gt'' donor sites are present, the use of these coding sequences with activation of the cryptic splicing donor sites could maintain the ORF. This hypothesis is now strongly supported by our finding that the suspected ''cryptic'' coding sequences in 14 cases are all located in intron 2, 13 of them followed by a gt signal. Nevertheless, to finally prove this hypothesis, the genomic structure of reciprocal chromosomal breaks on both PML and RAR␣ genes should be determined and compared with the corresponding mRNA sequence. Indeed, we have done just this in F1 and G-E076 cases, definitively resolving the sequence origin in these cases. This mechanism likely applies to many other cases, because cryptic splice sites are frequent in the genome (Ϸ1 in 300 bp). However, in V-type PML-RAR␣ genomic fusions, the use of these sites did not seem to be random in that some sites were recurrently used among different patients (Fig. 2 A) . Two reasons may explain this phenomenon. First, there must be coding sequences upstream of the sites allowing the rescue of the ORF. (32) . The extracted sequences flanking every RAR␣ t(15;17) breakpoint are shown aligned with each other on the match sites of the patterns found by MEME, and the 10 sequence positions preceding and following each site are also shown. ''ϩ'' means the forward extracted sequence, and ''Ϫ'' means the reverse complement of the extracted sequence. The P value gives the probability of a random string (generated from the background letter frequencies) having the same match score or higher. The multilevel consensus sequence corresponding to the pattern is an aid in remembering and understanding the pattern. The cases are sorted in increasing order by P value separately for each column of the pattern.
Second, sequences near these sites should be favorable for chromosomal translocation to occur. Notably, in most described genetic disease models, the splicing of an intronic sequence into mRNA caused by activation of ''cryptic'' splice sites resulted in the disruption of the ORF and therefore a ''loss of function'' mutation (41) . In contrast, in the V-form cases the use of cryptic splicing signals represents a ''gain of function'' mechanism. Interestingly, if the use of spacer sequence is not enough to maintain the ORF, there could be ''second line'' mechanism, as demonstrated by the presence of an S-type isoform in addition to an ''out of frame'' V-type isoform in case F2 in our work. This mechanism may be critical for APL cells to retain their growth advantage. Of note, in one report ⌬P6 and R3 sequences were directly joined without spacer sequences (24) . It is likely that potential splicing donor site is located immediately flanking the P6 breakpoint in this case.
Normally, RAR␣ has the ability to interact either with the transcriptional nuclear receptor coactivator apparatus or with the N-CoR͞Sin3͞HDAC1 CoR complex (2) . Under physiologic concentrations of RA, the interaction with the CoR is relieved, and RAR␣ functions as a transcription activator. Fusion of PML to RAR␣, however, results in an enhanced interaction with the CoR complex, thereby constitutively repressing RAR␣ target genes. This transcriptional repression can be relieved only when APL cells are treated with pharmacological concentrations of ATRA. In contrast, the association of CoR to PLZF-RAR␣ resists the modulating effect of ATRA because of the presence of a second CoR binding site on the PLZF moiety of the fusion protein (42) . Of note, APL cells with V-type isoform were reported to be less sensitive to ATRA (21) . One of the important findings of this work is the identification of a subset of V-type PML-RAR␣ cases with decreased ATRA sensitivity with regard to SMRT dissociation. This subset is characterized by a relatively long ''spacer'' with the same cryptic coding sequence (134 and 127 bp in cases F1 and G-E076, respectively) inserted into the joining sites between PML and RAR␣. Subsequent studies showed that deletion of this spacer restored the sensitivity to ATRA, suggesting it is the spacer sequence but not the truncation of exon 6, which is responsible for this aberrant binding to SMRT. Bioinformatics analysis suggested a possible protein-protein interaction motif in this spacer and deletion of this small motif decreased the binding to SMRT (Figs.  2B and 3A) . Interestingly, these two patients had a phenotype of clinical resistance to ATRA. On the other hand, the reported patients with APL of V-type PML-RAR␣ with short spacer sequence responded well to ATRA (24) . Our results have thus added more evidence to the model of transcriptional repression as the basal mechanisms of APL leukemogenesis and the relieving of this transcriptional repression as the major mechanism of differentiation therapy (Fig. 3B) .
Because nonrandom chromosomal translocations are crucial pathogenic events during leukemic transformation, an understanding of the genesis of these translocations is important. Here, we addressed this issue for RAR␣ gene sequences flanking the breakpoints of a number of previously reported patients. Although the study on breakpoints in RAR␣ intron 2 was limited by the probe selection in patients with t(15;17), at least two breakage hot spots were located within intron 2 of the RAR␣ gene. No heptamernanomer sequence reminiscent of V-D-J rearrangement of Ig gene, nor 4-bp duplication suggestive of Topo II effect, or long interspersed element͞short interspersed element sequences in favor of homologous recombination were found. However, some consensus patterns were found around the breakpoints (rarabpm1, rarabpm2, and rarabpm3), which may provide a chance for some protein recognition sites to stand out in the double helix of DNA. This hypothesis should be examined in further experiments.
